However, Fanni et al. find a significant increase of expression of CYP3A4 in HCC patients and overexpression of CYP3A4 gene could result in drug degradation or even a decreased therapeutic effect (Fanni et al., 2016). The gene discussed is CYP3A4; the disease is hepatocellular carcinoma.